Pages

Monday, March 30, 2020

Fw: (LML) Lepromin


 

Leprosy Mailing List – March 30, 2020

 

Ref.:   (LML)  Lepromin

 

From:  Ben Naafs, Munnekeburen, the Netherlands


 

Dear Pieter,

 

May be the users are of the opinion that one may sensitized when it is made from human or armadillo sources, because may contain human or armadillo antigens?

But I have not seen any convincing evidence for it.

 

Regards,


Ben


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/06a405fc-5cc9-4c6f-958d-bf4fb569fc8a%40googlegroups.com.

Fw: (LML) Lepromin

 


Leprosy Mailing List – March 30, 2020

 

Ref.:   (LML)  Lepromin

 

From:  Annemiek Geluk, Leiden, the Netherlands


 

 

Dear Pieter,

 

In the International Textbook of Leprosy there is a chapter included that amongst other topics also describes lepromin.

 

Perhaps this can be of use:

https://www.internationaltextbookofleprosy.org/chapter/immunodiagnostics-leprosy

 

 

Kind regards,

 

 

Annemieke

 

Prof. dr. A. Geluk – Dept. Infectious Disease – LUMC

                Immunodiagnostics of Leprosy & Tuberculosis

                https://www.universiteitleiden.nl/medewerkers/annemieke-geluk

                https://www.lumc.nl/org/infectieziekten/polikliniek/LepraDiagnostiek/


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/293489ff-3331-4647-92c2-cd9d87c01e40%40googlegroups.com.

Fw: (LML) Lepromin

 

Leprosy Mailing List –  March 30,  2020

Ref.:   (LML)  Lepromin

From:  Juan Periche Fernandez, Santo Domingo, Rep Dominicana


Dear Pieter,

Looking for help to assets the issue why lepromin is used very rarely nowadays.

Can't find papers on it but also interested in members opinions.

Thanks,

Dr. Juan Periche Fernandez
Medico-Dermatologo - Enfermedades de piel, uñas  y pelo

Director Programa de control de la lepra de Rep. Dom.
Coordinador Comite de etica interno (IRB) Co-coordinador de la
Residencia de Dermatologia Instituto Dermatologico y Cirugia de Piel Dr. Huberto
Bogaert Diaz (809)684-3257 ext 234  jperiche@hvtudr.org Movil (809)815-1060
Santo Domingo DN Rep Dominicana

Luchamos todos unidos por un mundo sin lepra


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/7a3d023c-99b5-41c7-a8e7-30b618caca79%40googlegroups.com.

Friday, March 27, 2020

Fw: (LML) Armadillos and Hansen's Disease in Brazil


 

 

 

Leprosy Mailing List – March 27,  2020

Ref.: (LML)    Armadillos and Hansen's Disease in Brazil

From:  Patricia Deps, Victória, Brazil


 

Dear Pieter,

The risk to human health of contact with armadillos infected with Mycobacterium leprae is uncertain, but evidence from Brazil and other countries appears to show a link between contact with armadillos and increased risk of Hansen's Disease in people. In the United States of America, Hansen's Disease is considered a zoonosis and contact with armadillos is a risk factor for the disease. In Brazil, the source of bacilli has been considered, almost exclusively, from those untreated multibacillary cases. However, we suppose that how much of Hansen's Disease in the human population is caused by contact with armadillos will depend on the size of the risk, the type and frequency of contact and how common it is in the population, and the role of other (human-to-human) transmission routes for Mycobacterium leprae (1).

In 2002, the first study demonstrating natural infection of Mycobacterium leprae in wild armadillos in Brazil was published (2). In the sequence, other studies were performed and antibodies anti-PGL-1 in wild armadillos were detected by ELISA and ML Flow test (3-5). In addition, a case control study conducted with persons affected by Hansen's Disease in the State of Espirito Santo (Brazil) also showed that direct contact with armadillo was a risk factor for developing the disease when compared with controls (6).


This week, a systematic review and meta-analysis about prevalence of Mycobaterium leprae infection in wild armadillos all over Brazil was published in PLOS Neglected Tropical Diseases (1). The 10 included studies represented a total sample of 302 armadillos comprising 207 (69%) Dasypus novemcinctus, 67 (22%) Euphractus sexcinctus, 16 (5%) Priodontes maximus, 10 (3%) Cabassous unicinctus, and 2 (1%) Cabassous tatouay from 7 different states (1).

I would like to share with you some key messages from this study:

1. The average prevalence of M. leprae in studies performed to date is equivalent to 1 in 10 armadillos being infected with M. leprae. However, we are not saying that 1 in 10 armadillos in Brazil are infected with M. leprae.

2. In a continental country as Brazil, three studies found zero infected armadillos, one study found that all of the captured armadillos were infected. The variation is what we would expect to see simply because the studies were relatively small. But it is also possible that there are real differences in M. leprae infection between armadillo populations in different parts of Brazil and in relation to the proximity of armadillo populations to human populations.

3. There were also some differences in methods between the studies, although all used a method for detecting M. leprae DNA which is highly sensitive.

4. Our results show that more of the same studies are not going to provide answers. Instead, we need bigger studies (capturing more animals across the whole of Brazil) and/or studies which investigate how M. leprae is carried in armadillo populations.

5. Finally, the proportion of Hansen's Disease in Brazil is attributable to contact with or consumption of armadillos is unknown. It might be a small proportion, and armadillos might just be part of an 'environmental pool' of M. leprae. But this might still have consequences for the elimination of Hansen's Disease in some communities. Therefore, it seems sensible to adopt the precautionary principle (discouraging people from capturing and eating armadillos). Thereby protecting people and armadillos.

References

1.    Deps PD, Antunes JM, Santos AR, Collin SM (2020) Prevalence of Mycobacterium leprae in armadillos in Brazil: A systematic review and meta-analysis. PLoS Negl Trop Dis 14(3): e0008127. https://doi.org/10.1371/journal.pntd.0008127

2.    Deps PD, Santos AR, Yamashita-Tomimori J. Detection of Mycobacterium leprae DNA by PCR in blood sample from nine-banded armadillo: preliminary results. Int J Lepr Other Mycobact Dis. 2002;70(1):34–5.

3.    Deps PD. Pesquisa de Mycobacterium leprae em tatus selvagens da espécie Dasypus Novencintus do Estado do Espírito Santo [Doutorado]. São Paulo: Universidade Federal de São Paulo; 2003. Available from: http://repositorio.unifesp.br/handle/11600/18627

4.    Deps PD, Antunes JM, Tomimori-Yamashita J. Detection of Mycobacterium leprae infection in wild nine-banded armadillos (Dasypus novemcinctus) using the rapid ML Flow test. Rev Soc Bras Med Trop. 2007;40(1):86–7.

5.    Deps PD, Antunes JM, Faria C, Buhrer-Sekula S, Camargo ZP, Opromola DV, et al. Research regarding anti-PGL-I antibodies by ELISA in wild armadillos from Brazil. Rev Soc Bras Med Trop. 2008;41 Suppl 2(SUPPL. 2):73–6.

6.    Deps PD, Alves BL, Gripp CG, Aragao RL, Guedes B, Filho JB, et al. Contact with armadillos increases the risk of leprosy in Brazil: a case control study. Indian J Dermatol Venereol Leprol. 2008;74(4):338–42.


Yours faithfully,

Patricia  Deps


Full Professor at the Department of Social Medicina, Postgraduate Programme in Infectious Diseases, Universidade Federal do Espirito Santo, Vitória-Brazil.
pdeps@uol.com.brpatricia.deps@ufes.br

 

Patricia Deps, MD, MSc, PhD
Dermatologist, Paleopathologist
Full Professor
Department of Social Medicine
Postgraduate Programme on Infectious Diseases
Federal University of Espirito Santo
Vitória-ES-Brazil

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/1ce29bcd-fc20-4504-8ab7-b747442d1bbb%40googlegroups.com.

Tuesday, March 24, 2020

Fw: (LML) GUIDELINES TO DOCTORS OF THE BRAZILIAN SOCIETY OF HANSEN’S DISEASE (SBH) ON THE POSSIBILITY OF COINFECTION LEPROSY AND COVID-19

 

Leprosy Mailing List – March 24,  2020


Ref.:  (LML)  GUIDELINES TO DOCTORS OF THE BRAZILIAN SOCIETY OF HANSEN'S DISEASE (SBH) ON THE POSSIBILITY OF COINFECTION LEPROSY AND COVID-19


From:  Claudio Salgado, Marituba, Brazil


Dear Pieter,

 

Considering the COVID-19 pandemic, the Brazilian Society of Hansen's Disease (SBH) decided to prepare brief guidelines on how to deal with the main issues that may arise during the coming months with leprosy patients, and we would like to share it with the LML community. Would you please publish on the LML? There are two versions, English and Portuguese. I am sending both here, annexed to this email.

 

Best Regards,


Claudio Salgado

====================================================

Claudio Guedes SalgadoMDPhD
President of the Brazilian Leprosy Society 2018-2020

Full Professor
Institute of Biological Sciences
Pará Federal University
Dermato-Immunology Laboratory

Av. João Paulo II, 113
Bairro: Dom Aristides
Marituba - Pará - Brasil
Zip Code: 67200-000

Mobile/Whatsapp: 55-91-991465641
E-mails: csalgado@ufpa.br and claudioguedessalgado@gmail.com

CV Lattes: http://lattes.cnpq.br/2310734509396125

ORCID ID: https://orcid.org/0000-0003-3961-7764

Linkedin: https://www.linkedin.com/in/claudio-guedes-salgado/

Lab Map: https://goo.gl/maps/7omyd54wy7z

Facebook: https://www.facebook.com/claudioguedessalgado


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/f1793724-790f-4250-b977-ca0b92f68ca1%40googlegroups.com.

Monday, March 23, 2020

Fw: (LML) Clofazimine supplies?

 

Leprosy Mailing List – March 23,  2020


Ref.:    (LML) Clofazimine supplies?


From:  Henk Eggens, Santa Comba Dão, Portrugal


 

Dear Pieter,


 

A quick internet search produced the info below:

 

Phare Pharmaceutical Enterprises Belgium Nv
(2627 Schelle Molenberglei 20 Belgium)
Phone:  +32 (0)38808760

Mr. Patrick Swolfs  (also Honorary Consul of Bangladesh in Belgium)
phone (+32) (0) 3 880 877 & (+32) 475 262 564 or email ps@phare.be

Phone numbers not tested by me. Not sure whether company Phare still exists.

Other address:
Phare
Satenrozen, 6A
2550 Kontich
België

I hope this helps

Henk Eggens

---
Henk Eggens

(henk.eggens@gmail.com)


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/ed3da69b-602e-4329-a775-a55ecd88cd40%40googlegroups.com.

Fw: (LML) Clofazimine supplies?

 

 

 

Leprosy Mailing List – March 23,  2020

Ref.:    (LML) Clofazimine supplies?


From:  Stefan Strahm, Zuerich, Switzerland


(Note editor: anybody who can help out? Which is what LML is all about!)

 

Dear Pieter Schreuder,

I would like to post an answer to the request of Ruth Butlins question about Clofazimine supplies (LML, March 17, 2020), but I am not able to do so. May I kindly request you to do it for me? The text is as follows:

*************

Dear all

In the past, I ordered loose Clofazimine in Belgium with PHARE S.A.,
Molenberglei 20, B-2627 Schelle, Belgium. I am not sure if they
are still producing Clofazimine.

Kind regards

Stefan Strahm

Stefan Strahm
Dennlerstrasse 16
CH-8048 Zuerich
Switzerland


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/ecafbfa0-ead4-448e-84ad-f7d1f5a6c23e%40googlegroups.com.

Fw: (LML) Urgent: MDT during COVID-19 pandemic


 

 

Leprosy Mailing List – March 23,  2020

Ref.:   (LML)  Urgent: MDT during COVID-19 pandemic

From:  Ben Naafs, MUnnekeburen, the Netherlands


Dear Pieter,


Yesterday, we saw Joël's cri de Coeur. Although, I am not an expert on Corona, I like to contribute and hope to make some common sense.


The advice to stay at home is easily given, however for many people difficult to follow. If you must go out to work, buy food or get medicine, then the following is very important. Do not go out when you cough and/or have a sore throat and fever. If possible, let others do what must be done.


But in case you are out, most important is stay at least 1,5 meters from other people. The common mouth caps only protect other people from you. Only special ones protect you from others. Thus the 1,5 meters is important.


When you come home first clean your phone with antiseptic. Then wash your hands with water and soap. Next, clean your face. And then in the old-fashioned way gargle with salt solution. This may be repeated later before going to bed. Clean water is adamant both for washing and gargling. Since soap is not good for your skin use vaseline without additives. For the face Nivea crème or similar is excellent. Treat your children in the same way.


Thereafter, if possible, change clothes and wash the used ones. If you haven't enough clothes stay in underpants until the washed clothes are dry again. If possible, change clothes before you wash or wash again after change.


During work wash your hands and face regularly and apply vaseline on your hands and crème on your face. Clean the materials you work with and on with alcohol or antiseptic. Use your common sense.


We stand for a serious outbreak.

 

Regards

 

Ben


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/d13d8295-e34c-41f0-b0b5-da66e70a1aea%40googlegroups.com.

Sunday, March 22, 2020

Fw: (LML) Urgent: MDT during COVID-19 pandemic

Leprosy Mailing List – March 22,  2020

Ref.:   (LML)  Urgent: MDT during COVID-19 pandemic

From:  Joel Almeida, London and Mumbai


 

Dear Pieter and colleagues,

 

Monthly collection of MDT is compromised by social isolation practices. These practices might prove necessary for an inconveniently long duration.

 

Please consider protecting your patients by giving them sufficient number of blister packs of MDT to take home, at the first opportunity. In hyper-endemic areas, this is important also for reducing the transmission of HD between persons with the LLp genome(s). Otherwise we could suffer a setback in HD control over the coming years. Please forward this to your local government official who supervises the local stocking and supply of MDT.

 

In TB we (at WHO) insisted that a full course of treatment should be supplied to the patient's designated observer in a "patient-wise box" at the start of treatment. This was important to eliminate stock-outs of drugs for the individual patient. This may be worth considering in HD (Hansen's disease) too, even beyond the end of this pandemic.

 

Meanwhile, please stay at a safe distance from others so that the transmission of the Sars-CoV-2 virus can be slowed down. We cannot afford to lose members of our community prematurely, if we are to defeat the HD bacillus permanently.

 

Joel Almeida

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/24f771d3-4a70-42b1-90df-43325bfe4610%40googlegroups.com.

Friday, March 20, 2020

Fw: (LML) WHO Goodwill Ambassador's Newsletter for the Elimination of Leprosy No. 99

 

Leprosy Mailing List – March 20,  2020


Ref.:    (LML) WHO Goodwill Ambassador's Newsletter for the Elimination of Leprosy No. 99


From:  Takahiro Nanri, Tokyo, Japan


 

Dear Dr. Schreuder and Friends,  

 

Warm greetings from Sasakawa Health Foundation in Tokyo. We have uploaded the latest issue of the "WHO Goodwill Ambassador's Newsletter for the Elimination of Leprosy" (No. 99) to our website

In this issue, we feature: 

- Message: From Tokyo to the World
- Global Appeal 2020:
   Advocating social inclusion
   Torch-bearer for the appeal
   Text of Global Appeal 2020
   Difference is natural
- Ambassador's Journal: INDIA
- News: Special Rapporteur visits Japan
- From the Editor  

We hope you enjoy our latest issue and welcome your comments and contributions to the newsletter. 

 

BACK ISSUES

https://www.shf.or.jp/information/g/ambassador?lang=en

 

    

Takahiro NANRI, Ph.D.

Executive Director

 

Hansen's Disease Program

Sasakawa Health Foundation

Tel81-3-6229-5377, Fax81-33-6229-5388

email: hansen@shf.or.jp

visit our website at https://www.shf.or.jp


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/6595479c-1aa4-41a7-8852-4f2a5a73f114%40googlegroups.com.

Fw: (LML) Helping small Pacific populations to become HD-free


 

Leprosy Mailing List – March 20,  2020


Ref.:    (LML) Helping small Pacific populations to become HD-free

From:  Joel Almeida, London and Mumbai


 

Dear Pieter and colleagues,

 

There are many atolls and small islands scattered over millions of square miles in the Pacific Ocean. Some have very small populations. Access is difficult. People from some of these islands have the right to move freely to and from the USA, and they often exercise this right. 

 

Some esteemed colleagues have been discussing with me how best to eliminate HD from these small island populations. 

 

One approach being tried is to use two annual rounds of population-wide chemoprophylaxis, accompanied by multi-year chemoprophylaxis for contacts of cases. Rifampicin is being proposed instead of the rifampicin+ofloxacin+minocycline (ROM) previously given population-wide in some Pacific islands (1). That population-wide ROM, including two separate doses for many individuals, had very little long-term impact. HD returned after a lull. That may well have been because the mass drug campaigns failed to diagnose LLp patients who lacked obvious physical signs.. 

 

What is likely to happen with the rifampicin-only approach?

 

"De novo" LL disease is known to show few or no obvious physical signs. A single dose of rifampicin kills roughly 90% of viable bacilli. Therefore each dose of rifampicin is likely to produce a roughly 10-fold boost in the frequency of rifampicin-resistant mutant bacilli in the surviving bacillary population of a person with missed HD. After 2 annual doses of rifampicin, such persons are likely to show a 100-fold boost in the frequency of rifampicin-resistant bacilli among their surviving bacilli. If undiagnosed LLp persons happen also to be contacts of newly diagnosed HD patients, they will be due to receive a further dose of rifampicin. This third dose is likely to contribute to a frequency of rifampicin-resistant mutants 1000-fold greater than in rifampicin-naive bacillary populations. These pre-selected bacillary populations with boosted rifampicin-resistant mutants, especially in persons with missed LLp HD, can then serve as the main source of HD bacilli in the human population. 

 

Therefore, the intervention is likely to be followed by an eventual resurgence of HD in the population, but this time with rifampicin-resistant HD. This resurgence will likely be temporarily disguised by the delay of obvious physical signs in persons with the LLp genome(s), and by the incubation period of other types of HD in those newly infected. This delay is likely to be measured in years rather than months. So, the eventual impact will not become apparent until some years have passed.

 

Drug-resistance is of great help to HD bacilli, but unhelpful to the people of these islands. It could enable HD to continue for generations. This form of HD, however, will be more dangerous because of rifampicin-resistant bacilli. 

 

Excluding covert "de novo LL" HD would help greatly. Therefore, the most reliable sequence of measures is probably:

 

1. Clinical examination and serology to exclude covert undiagnosed LL disease. If positive serology, then skin smears to identify LL patients so that they can be given prolonged anti-microbial protection (eg., not just MDT but also subsequent monthly multi-drug chemoprophylaxis to protect them against recurrence of HD). All newly diagnosed HD patients to receive MDT.

 

2. A dose of multi-drug chemoprophylaxis in the remaining population.

 

3. A few days later, BCG (re)vaccination in those who received the chemoprophylaxis. Or, MIP vaccine in place of BCG.

 

This can probably be implemented best by a mobile team of well-trained professionals who visit each atoll once or twice a year. They can supervise the campaign and train local general-purpose health staff (eg., for nerve function monitoring and prompt appropriate steroid use when needed). This approach could well lead to a sustained 20%/year decline in HD ending in near-zero transmission, with near-zero new disability and declining stigma. 

 

The use of multi-drug chemoprophylaxis, instead of rifampicin on its own, would avert a legacy of rifampicin-resistant HD. Instead, we could achieve an HD-free Pacific.

 

Joel Almeida

 

References

 

1. Diletto C, Blanc L, Levy L. Leprosy chemoprophylaxis in Micronesia. Lepr Rev. 2000;71(Suppl):S21–3.


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/c10f3181-29ad-48a4-8095-d7d56e9f305a%40googlegroups.com.